Partnering is of key importance at AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe.
AOP Orphan is focusing on three different ways of partnering:
In all cases, a trusting collaboration is based on:
Partnering is focused on the key treatment areas of:
In addition to these, AOP Orphan is open for further treatments in the field of rare diseases as well as specialty products. The complexity of the treatment areas requires long-term cooperation with all stakeholders in the healthcare system. For this reason, partnering is usually designed to continue for an extended period of time beyond the product life cycle.
For AOP Orphan, partnering can go both ways – as a partner for pharmaceutical companies that wish to place their product in AOP Orphan’s core markets, or as a licensor for in-house developments that will be distributed by partners in other countries. In both cases, a trusting win-win collaboration of reliable partner, having expertise and a passion for the project at hand.